ReviewCells2021
Ventricular Arrhythmias in Ischemic Cardiomyopathy-New Avenues for Mechanism-Guided Treatment.
Review in Cells, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- Development and validation of a risk prediction model for in-hospital mortality among patients with acute myocardial infarction complicated by ventricular arrhythmia.BMC cardiovascular disorders · 2026Article
- Selective RyR2 inhibition reduces arrhythmia susceptibility in human cardiac slices.The Journal of physiology · 2026Article
- CMR-quantified epicardial adipose tissue heterogeneity and its predictive value for ventricular and atrial arrhythmias after myocardial infarction.BMC medical imaging · 2026Article
- Cardiac endogenous transmitter system: molecular features, functions, and clinical implications.European heart journal · 2026Review
- SASP-mediated cellular senescence following myocardial infarction: from spatiotemporal immune regulation to therapeutic strategies.Frontiers in immunology · 2026Review
- Review
- Acute gross and histopathologic changes after ischaemic ventricular tachycardia ablation.European heart journal. Case reports · 2025Article
- Imaging application in ventricular arrhythmia of ischemic cardiomyopathy: diagnosis, treatment and prognosis.Echo research and practice · 2025Review
- Gene Therapy for Cardiac Arrhythmias: Mechanisms, Modalities and Therapeutic Applications.Medical sciences (Basel, Switzerland) · 2025Review
- Comparative analysis of the ten Tusscher and Tomek human ventricular cell models at cellular, tissue, and organ levels: Implications for post-infarct ventricular tachycardia simulation.Physiological reports · 2025Article
- The Role of Infarct Border Zone Remodelling in Ventricular Arrhythmias: Bridging Basic Research and Clinical Applications.Journal of cellular and molecular medicine · 2025Review
- Heart Failure and Arrhythmias: Circadian and Epigenetic Interplay in Myocardial Electrophysiology.International journal of molecular sciences · 2025Review
- Electrocardiographic imaging metrics to predict the risk of arrhythmia in patients with ischemic cardiomyopathy.Journal of arrhythmia · 2025Article
- Magnetic resonance imaging quantification of left ventricular mechanical dispersion and scar heterogeneity optimize risk stratification after myocardial infarction.BMC cardiovascular disorders · 2025Article
- Mitochondrial dysfunction as a central hub linking NaFrontiers in cardiovascular medicine · 2025Review
- The Impact of Coronary Ischemia Assessment on Outcomes in Those With Scar-Dependent Ventricular Tachycardia.Journal of cardiovascular electrophysiology · 2025Article
- Article
- Evaluating computational efforts and physiological resolution of mathematical models of cardiac tissue.Scientific reports · 2024Article
- Catheter Ablation of Ventricular Tachycardia in Ischemic Heart Disease: What Is Known and New Perspectives.Current heart failure reports · 2024Review
- Multiparametric Mapping via Cardiovascular Magnetic Resonance in the Risk Stratification of Ventricular Arrhythmias and Sudden Cardiac Death.Medicina (Kaunas, Lithuania) · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Ischemic heart disease is the most common cause of lethal ventricular arrhythmias and sudden cardiac death (SCD). In patients who are at high risk after myocardial infarction, implantable cardioverter defibrillators are the most effective treatment to reduce incidence of SCD and ablation therapy can be effective for ventricular arrhythmias with identifiable culprit lesions. Yet, these approaches are not always successful and come with a considerable cost, while pharmacological management is often poor and ineffective, and occasionally proarrhythmic. Advances in mechanistic insights of arrhythmias and technological innovation have led to improved interventional approaches that are being evaluated clinically, yet pharmacological advancement has remained behind. We review the mechanistic basis for current management and provide a perspective for gaining new insights that centre on the complex tissue architecture of the arrhythmogenic infarct and border zone with surviving cardiac myocytes as the source of triggers and central players in re-entry circuits. Identification of the arrhythmia critical sites and characterisation of the molecular signature unique to these sites can open avenues for targeted therapy and reduce off-target effects that have hampered systemic pharmacotherapy. Such advances are in line with precision medicine and a patient-tailored therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.